Phase I/II trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC)

Phase I/II trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC)

Apr 10, 2024

The findings presented at the 2024 AACR conference revealed that among patients diagnosed with PIK3Ca-mutated MSS mCRC (n = 22), three patients attained a partial response (PR). Additionally, one more patient with PIK3Ca-mutated mCRC maintained stable disease (SD). The study successfully achieved its primary endpoint of overall response rate at 6 months in the PIK3Ca-mutant subgroup, as responses were evident in a minimum of three patients.

Within the PIK3Ca wild-type subgroup (n = 17), one patient achieved a partial response (PR) despite lacking a PIK3Ca mutation. Additionally, four other patients in the same cohort exhibited stable disease (SD).

Conclusion

Copanlisib plus nivolumab elicited PRs in only a minority of patients, that subgroup experienced a significant clinical benefit.

loader